Evaluation of gradient strip diffusion for susceptibility testing of aztreonam-avibactam in metallo-β-lactamase-producing Enterobacterales

被引:0
|
作者
Lemon, Jamie K. [1 ,2 ]
Jankowsi-Romano, Cheryl [1 ]
Duong, Scott [1 ,2 ]
Juretschko, Stefan [1 ,2 ]
Streva, Vincent A. [1 ,2 ]
机构
[1] Northwell Hlth Clin Labs, New York, NY 10075 USA
[2] Donald & Barbara Zucker Sch Med Hofstra Northwell, Manhasset, NY 11549 USA
关键词
metallo-beta-lactamase; aztreonam-avibactam; antimicrobial susceptibility testing; NDM; gradient strip diffusion;
D O I
10.1128/jcm.00649-24
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The emergence of metallo-beta-lactamase (MBL)-producing Enterobacterales presents unique clinical treatment challenges. Recently developed beta-lactam/ beta-lactamase inhibitor combination agents, while effective against other carbapenemase-producing organisms, are notably ineffective against MBL producers. While MBLs do not hydrolyze monobactams (aztreonam), many MBL-producing organisms are resistant to aztreonam through alternate mechanisms, leaving cefiderocol as the sole monotherapy treatment option recommended for MBL producers. Recent guidelines for the treatment of MBL-harboring organisms have added combination therapy with aztreonam and ceftazidime-avibactam, using ceftazidime-avibactam as a source of the beta-lactamase inhibitor avibactam. Current laboratory testing options for the combination of aztreonam-avibactam are limited to broth microdilution (BMD) and broth disk elution (BDE) methods, which are not practical in most clinical laboratories. In this study, we evaluated the performance of aztreonam/avibactam gradient strips on 103 MBL-producing Enterobacterales patient isolates as well as an additional 31 isolates from the CDC AR Bank. All MBL Enterobacterales patient isolates included in this study harbored a New Delhi metallo-beta-lactamase (blaNDM) gene. Essential agreement of gradient strip minimal inhibitory concentrations (MICs) for patient isolates compared to BMD was 93.2%. While there are no established breakpoints for aztreonam-avibactam, category agreement (CA) for patient isolates was 97.1% when using the CLSI aztreonam breakpoints. There were no major or very major errors observed. There were three minor errors. Precision for aztreonam-avibactam gradient strip diffusion was 100%. These data demonstrate that the use of gradient strip diffusion for aztreonam-avibactam MIC determination in MBL-producing Enterobacterales is a viable option for clinical laboratories.
引用
收藏
页数:10
相关论文
共 50 条
  • [1] Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales
    Cardot Martin Emilie
    Colombier Marie Alice
    Gougeon Marine
    Eric Farfour
    Annabelle Pourbaix
    Laurent Dortet
    Limousin Lucie
    Vasse Marc
    European Journal of Clinical Microbiology & Infectious Diseases, 2024, 43 : 777 - 784
  • [2] Evaluation of the MTS™ aztreonam-avibactam strip (Liofilchem) on New Delhi metallo-β-lactamase-producing Enterobacterales
    Emilie, Cardot Martin
    Alice, Colombier Marie
    Marine, Gougeon
    Farfour, Eric
    Pourbaix, Annabelle
    Dortet, Laurent
    Lucie, Limousin
    Marc, Vasse
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (04) : 777 - 784
  • [3] In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
    Wang, Wen
    Huang, Shifeng
    Zou, Chunhong
    Ding, Yanhui
    Wang, Huijuan
    Pu, Shuli
    Liao, Yunfeng
    Du, Hong
    Wang, Deqiang
    Chen, Liang
    Niu, Siqiang
    FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY, 2021, 11
  • [4] Genetic Features Leading to Reduced Susceptibility to Aztreonam-Avibactam among Metallo-β-Lactamase-Producing Escherichia coli Isolates
    Sadek, Mustafa
    Juhas, Mario
    Poirel, Laurent
    Nordmann, Patrice
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2020, 64 (12)
  • [5] In Vitro Activities and Inoculum Effects of Cefiderocol and Aztreonam-Avibactam against Metallo-β-Lactamase-Producing Enterobacteriaceae
    Huang, Yu-Shan
    Chen, Pao-Yu
    Chou, Pei-Chun
    Wang, Jann-Tay
    MICROBIOLOGY SPECTRUM, 2023, 11 (03):
  • [6] Aztreonam Combinations with Avibactam, Relebactam, and Vaborbactam as Treatment for New Delhi Metallo-β-Lactamase-Producing Enterobacterales Infections-In Vitro Susceptibility Testing
    Brauncajs, Malgorzata
    Bielec, Filip
    Malinowska, Marlena
    Pastuszak-Lewandoska, Dorota
    PHARMACEUTICALS, 2024, 17 (03)
  • [7] In vitro activity of aztreonam-avibactam against metallo-β-lactamase-producing Enterobacteriaceae-A multicenter study in China
    Zhang, Biying
    Zhu, Zhichen
    Jia, Wei
    Qu, Fen
    Huang, Bin
    Shan, Bin
    Yu, Hua
    Tang, Yiwei
    Chen, Liang
    Du, Hong
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2020, 97 : 11 - 18
  • [8] In Vitro Susceptibility of Aztreonam-Vaborbactam, Aztreonam-Relebactam and Aztreonam-Avibactam Associations against Metallo-β-Lactamase-Producing Gram-Negative Bacteria
    Emeraud, Cecile
    Bernabeu, Sandrine
    Dortet, Laurent
    ANTIBIOTICS-BASEL, 2023, 12 (10):
  • [9] Pilot Program for Aztreonam-Avibactam Susceptibility Testing of Metallo-Beta-Lactamase-Producing Enterobacteriaceae
    Bhatnagar, Amelia
    Malik, Sarah
    Karlsson, Maria
    Lonsway, David
    Lutgring, Joseph
    Huang, Jennifer
    Gumbis, Stephanie
    Brown, Allison
    INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY, 2020, 41 : S74 - S75
  • [10] Efficacy of Ceftazidime-avibactam Plus Aztreonam in Patients With Bloodstream Infections Caused by Metallo-β-lactamase-Producing Enterobacterales
    Falcone, Marco
    Daikos, George L.
    Tiseo, Giusy
    Bassoulis, Dimitrios
    Giordano, Cesira
    Galfo, Valentina
    Leonildi, Alessandro
    Tagliaferri, Enrico
    Barnini, Simona
    Sani, Spartaco
    Farcomeni, Alessio
    Ghiadoni, Lorenzo
    Menichetti, Francesco
    CLINICAL INFECTIOUS DISEASES, 2021, 72 (11) : 1871 - 1878